Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform. Source: Pixabay According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previou ...

I'm a full time value investor and writer who enjoys using classical value ratios to pick my portfolio. Long-term focused on low P/B, P/FCF, Owner Earnings discounting, PEG ratios, the Graham Number and an occasional net-net hunter. I also believe tracking earnings growth versus price appreciation is an essential element to any quality evaluation.I also advocate self-indexing primarily using the Dow Jones Industrial Average as my index of choice combined with Joel Greenblatt's Magic Formula. This can help w ...

Group 1 - The article discusses the process of identifying stocks for investment by running a simple screening method to find potential candidates for deeper analysis [1] - The author has extensive experience in various investment vehicles including commodities, stocks, options, and futures contracts, leading to a successful trading career [1] Group 2 - There is a disclosure regarding a beneficial long position in the shares of IESC, indicating a personal investment interest [2] - The article emphasizes that past performance does not guarantee future results, highlighting the inherent uncertainties in investment [3]